The optimization of recombinant antibody production within Chinese hamster ovary (CHO) cells remains a paramount challenge to the biopharmaceutical industry. A variety of strategies can be employed maximize antibody titer, comprising process parameter optimization, cell line development, and implementation of perfusion processes. Fine-tuning medi